Precigen
Update in progressPGEN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies with precision technology to treat immuno-oncology, autoimmune diseases, and infectious disorders. Its platforms include AdenoVerse, for delivering therapeutic effectors, immunomodulators, and vaccines, and UltraCAR-T for CAR-T therapies. Programs include PRGN-3005, -3006, -3007, AdenoVerse PRGN-2009 and PRGN-2012, plus UltraPorator. Formerly Intrexon, renamed 2020; founded 1998; based in Germantown, MD.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.53
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Helen Sabzevari MPH, Ph.D.
- Founded1998
- Employees160
- Websiteprecigen.com
Identifiers
- ISINUS74017N1054
- FIGIBBG000QL8VH9
- LEI549300XCWNQU35K64G19
- CUSIP46122T102
- CIK0001356090